Passage Bio Inc (Passage Bio) is a genetic medicines company that develops therapies for the treatment of monogenic central nervous system disorders. The company's pipeline products include PBGM01 injection to treat GM1 gangliosidosis, PBFT02 for the treatment of frontotemporal dementia (FTD), and PBKR03 for the treatment of infantile Krabbe disease, PBML04 for the treatment of metachromatic leukodystrophy and PBAL05 for the treatment of neurodegenerative disease. Passage Bio works in collaboration with the University of Pennsylvania and its gene therapy program (GTP) for preclinical works. The company also conducts clinical development, regulatory strategy, and commercialization activities. Its manufacturing and global clinical distribution center is located at Hopewell, New Jersey. Passage Bio is headquartered in Philadelphia, Pennsylvania, the US.
Headquarters
United States of America
Address
One Commerce Square, 2005 Market Street, 39th Floor, Philadelphia, Pennsylvania, 19103
Website
www.passagebio.com
Telephone
1 267 8660312
No of Employees
58
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PASG (NASD)
EPS
XYZ
Net Income (2022)
XYZ
25%
(2022 vs 2021)
Market Cap*
$78.3M
* As of and is in US$
Passage Bio Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| PBGM01 (to treat GM1 Gangliosidosis) |
| PBML04 (to treat Metachromatic leukodystrophy) |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Passage Bio Inc | Denali Therapeutics Inc | Arcturus Therapeutics Holdings Inc | Alector Inc | Orchard Therapeutics Plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Philadelphia | South San Francisco | San Diego | South San Francisco | London |
| State/Province | Pennsylvania | California | California | California | England |
| No. of Employees | 58 | 445 | 170 | 244 | 166 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William Chou, M.D | Chief Executive Officer; President; Director | Executive Board | 2022 | 50 |
| Mark Forman | Chief Medical Officer | Senior Management | 2021 | 59 |
| Desiree Luthman | Senior Vice President - Global Regulatory Affairs | Senior Management | 2021 | - |
| Edgar B. Cale | General Counsel; Secretary | Senior Management | 2019 | 59 |
| James M Wilson | Chief Scientific Advisor | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward